Oxygen Biotherapeutics Management
News & Events
Oxygen Biotherapeutics Announces Collaboration with Imperial College London to Accelerate Enrollment of LeoPARDS Trial
Company to support a 500+ patient study assessing benefit of levosimendan in septic shock patients
Wednesday, August 6, 2014 8:00 am EDT
Public Company Information:
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial (Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis) awarded by the Efficacy and Mechanism Evaluation (EME) Programme and funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Oxygen is also currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS). more..
Our management team represents decades of experience and expertise in biomedical product R&D, regulatory and clinical affairs, GMP compliant manufacturing, international business, and global marketing.
Chief Executive Officer
Mr. John Kelley has been Chief Executive Officer of Oxygen Biotherapeutics, Inc. since November 14, 2013. Mr. Kelley co-founded Phyxius Pharma, Inc. in 2011 and served as its CEO. Mr. Kelley has served in many senior level executive positions within the pharmaceutical industry, including: President/Chief Operating Officer at The Medicines Company; Senior Vice President of Global Medical and Marketing at Aventis Pharmaceuticals; Vice President of Strategic Development and Mergers & Acquisitions at Aventis Pharmaceuticals; and Vice President and Head of US Commercial at Hoechst Marion Roussel. Mr. Kelley's experience includes work on several successful cardiovascular and critical care brands including, Angiomax, Lovenox, Cardizem, and Altace as well as other large non cardiovascular brands including Lantus, Copaxone, Allegra, and Actonel. He serves as a Director of Acorda Therapeutics.
Mr. Kelley received a B.S. degree in Biology from Wilkes University and an MBA degree from Rockhurst University.
Michael B. Jebsen
Chief Financial Officer
Mr. Jebsen was named Interim Chief Executive Officer in August 2011, while retaining his role as Chief Financial Officer and Treasurer. He joined Oxygen as our Accounting Manager in April 2009 and was elected CFO in August 2009. Before joining Oxygen, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009. In addition, he held various positions, including Chief Ethics Officer, Senior Internal Auditor, and Senior Financial Analyst with RTI International, a non profit research and development organization, from January 2006 to February 2008. Mr. Jebsen holds a Master of Science in Accounting from East Carolina University and is a certified Public Accountant, licensed in North Carolina.
Vice President of Commercial and Business Operations
Mr. Randall has 31 years of pharmaceutical executive experience. Prior to joining the company, Mr. Randall co-founded Phyxius Pharma, Inc. in 2011 where he served as the Chief Commercial Officer. Previously, Mr. Randall served in many senior level executive positions within the pharmaceutical industry, including: Vice President of Commercial Operations at The Medicines Company; Vice President of US Diabetes Marketing at Sanofi-Aventis Pharmaceuticals; and Vice President of Sales at Aventis Pharmaceuticals. Prior to the formation of Aventis Pharmaceuticals in 2000, Mr. Randall served in several senior commercial roles at the former legacy companies (Hoechst Marion Roussel, Marion Merrell Dow, and Marion Laboratories) including: Director of Respiratory Marketing, Director of Cardiovascular marketing, Director of GI/CNS Marketing, Director of Distribution and Pharmacy Markets, and various sales management roles. Mr. Randall started his pharmaceutical career as a sales representative for Marion Laboratories, Inc. in 1982 after earning his B.S. in Pharmacy from the University of Rhode Island.
Douglas Hay, PhD
Vice President of Regulatory Affairs
Dr. Hay has over 27 years pharmaceutical regulatory experience. Prior to joining the company Dr. Hay was a co-founder of Phyxius Pharma, Inc. where he served as Vice President of Regulatory Affairs. Previously, Dr. Hay lead positions in global regulatory affairs at The Medicines Company and Shire Pharmaceuticals. He spent the majority of his career at Bristol Myers Squibb where he advanced to Vice President, Global Regulatory Sciences. This experience spans drug development (Phase 1-4) in numerous therapeutic areas, including the development of novel biologics and new chemical entities. Dr. Hay’s experience has included responsibility for development projects in virtually all major cardiovascular classes, including development/registration programs for Capoten, Monopril, Avapro, Plavix, and Angiomax. Doug received his AB degree in Biology from University of California, Riverside, MS in biology at California State University, Long Beach, and PhD (physiology emphasis) from Northern Arizona University.
Tim Bradshaw, PhD
EVP Clinical Development
Dr. Bradshaw joined Oxygen Biotherapeutics, Inc. in 2010 and since that time has been responsible for all areas of Oxycyte development including preclinical research, clinical trials, and manufacturing. He has over twenty years of leadership experience in the pharmaceutical industry and clinical CRO arenas.
Following his doctoral work in protein chemistry and enzymology, Dr. Bradshaw worked in post-doctoral fellowship positions in pharmacology (Medical University of South Carolina) and drug metabolism (Glaxo Research Institute). He went on to become a leader in GlaxoWellcome’s efforts to develop biopharmaceutical products before his interests evolved from compound discovery and development to clinical research. In 2000, he was recruited to assist in the design and implementation of a clinical operations model for the newly formed GlaxoSmithKline. Prior to joining Oxygen Biotherapeutics, Dr. Bradshaw spent two years at Talecris Biotherapeutics where he was Deputy Program Manager and responsible for the company’s franchise product, Gamunex, as well as efforts to develop human and recombinant forms of the thrombolytic, plasmin, for treating acute ischemic stroke and peripheral artery disease.
At Oxygen Biotherapeutics, Dr. Bradshaw has been instrumental in guiding the traumatic brain injury trial to a successful conclusion for the first cohort and is currently focused on expanding the study in additional countries. Dr. Bradshaw earned his BA in Chemistry from Erskine College and a Ph.D. in Biochemistry from the University of South Carolina.
EVP, Legal Affairs, General Council, and Corporate Secretary
Ms. Hecox joined Oxygen as General Counsel in October 2009. She brings over a decade of experience in the pharmaceutical/biotech industry from prior positions with Becton Dickinson, eTrials Worldwide, Quintiles, and DSM Pharmaceuticals. Ms. Hecox holds a BS degree in Communications from the State University of New York and an MBA from East Carolina University. She received her JD degree from North Carolina Central University, graduating cum laude, and is admitted to the North Carolina State Bar.